Myeloma UK reveals new Director of Research appointment

pharmafile | November 14, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Myleoma UK, appointment, multiple myeloma, pharma 

UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, who in her new role will galvanise research and patient advocacy efforts within the company in the spirit of “advancing the organisation’s impact within the blood cancer research community”.

McDonald joins the organisation from fellow non-profit Sarcoma UK where she served as Director of Research and Policy. In the role, she led the organisation’s research programme and was a key player in securing £870,000 worth of funding for its clinical, lab-based and genomic research projects. She joined the group in 2014 as its Director of Research, Information and Support Services.

Prior to this, McDonald worked at the University of Sussex as its Senior Research Development Officer, and has also held Senior and Head Biomedical Scientist roles at a range of NHS Trusts and hospitals.

“We are thrilled to welcome Sarah McDonald to Myeloma UK,” commented Marc Gordon, Chairman at the organisation. “Sarah has outstanding experience in research management and patient advocacy within the cancer research sector. Her impressive skills and knowledge will be a huge asset to our organisation.”

McDonald herself said of her appointment: “I am delighted to be joining Myeloma UK as the Director of Research. The organisation has done so much for patients not just in treatment access and new treatment development but also the outstanding support services that we provide to anyone affected by a diagnosis of myeloma.

“My research background has centred on diagnosis and the power of using samples for research to investigate diagnostic and prognostic markers for cancer,” she continued. “Having spent the last 25 years working in cancer, I have seen the positive impact that effective research can have, and Myeloma UK are committed to finding answers so that patients can have longer and better lives to spend with their families. I can’t wait to get started and build on the excellent work that the MUK trials are doing so that we can help ensure that new treatment options will be available for patients in the future.”

Related Content


GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

GSK has announced positive results from a planned interim efficacy analysis of the phase 3 …


FDA grants ODD to NXC-201 as multiple myeloma treatment

Nexcella has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug …

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Latest content